Please login to the form below

Not currently logged in
Email:
Password:

InterMune

This page shows the latest InterMune news and features for those working in and with pharma, biotech and healthcare.

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Roche acquired Esbriet when it spent $8.3bn in 2014 to buy InterMune, the company which developed the drug, and has seen its sales grow steadily to a level of CHF

Latest news

More from news
Approximately 4 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    InterMune/ Roche. Company acquisition. Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada).

  • Pharma deals during August 2014 Pharma deals during August 2014

    Instead came the news that Roche had beaten a host of companies including Sanofi, GSK, Actelion and Gilead in the acquisition of InterMune for $8.3bn ($74.00 a share, representing ... InterMune is also developing a pirfenidone analogue to treat specialty

  • Orphan indication? No easy access Orphan indication? No easy access

    Only the case of Intermune's idiopathic pulmonary fibrosis drug Esbriet (perfenidone) was the balance of benefit and risk to patients considered and a finding of 'no proven added benefit' was

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    Prior to joining Catabasis, Modi was senior vice president, global marketing at InterMune - an orphan drug company that was acquired by Roche late last year. ... He played a large role in the launch of InterMune's flagship product, the lung-scarring drug

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

Transforming healthcare through effective collaboration. Making work to feel proud of. www.dovetailstrategies.com...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics